Search - tctmd.com

Displaying 41 - 52 of 52

Sort: Relevancy | Date

Presentation TVT 2021

With a Hypercoagulable Condition: Is PFO Closure More Important, More Dangerous, or Both?

Presenter: Julia Seeger

July 22, 2021

Presentation TVT 2021

Do We Need a NOAC vs PFO Closure Trial?

Presenter: John Carroll

July 22, 2021

News Industry News

BIOMODEX Technology Enables New Milestone in Interventional Cardiology

July 21, 2021

Presentation TVT 2021

Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System for Severe Tricuspid Regurgitation: A Multicenter, First-in-Human 1-Year Observation

Presenter: Ming-yu (Anthony) Chuang

July 21, 2021

Presentation TVT 2021

First Commercial Multicenter Experience With the PASCAL Transcatheter Valve Repair System for Tricuspid Regurgitation

Presenter: Jörg Hausleiter

July 21, 2021

Presentation TVT 2021

First Report of 2-Year Outcomes With a Next-Generation Left Atrial Appendage Closure Device: Final Results From the PINNACLE FLX IDE Trial

Presenter: Saibal Kar

July 21, 2021

News Daily News

Predictors of Device-Related Thrombus Following LAA Occlusion

Shelley Wood

July 19, 2021

News Conference News ACC 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

Todd Neale

May 15, 2021

News Conference News ACC 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

Todd Neale

May 15, 2021

News Daily News

LAA Occlusion With Amplatzer Amulet May Have Edge Over DOACs

Todd Neale

January 08, 2021

Video

» Interview

AMULET IDE: One-Year Device Closure and Device-Related Thrombus Outcomes From a Randomized Trial of Amulet versus Watchman for Left Atrial Appendage Occlusion

November 5, 2021

Video

» Interview

SWISS-APERO: A Randomized Trial of the Amulet Versus Watchman FLX Devices for Left Atrial Appendage Closure

November 5, 2021

Advertisement

With a Hypercoagulable Condition: Is PFO Closure More Important, More Dangerous, or Both?

Do We Need a NOAC vs PFO Closure Trial?

BIOMODEX Technology Enables New Milestone in Interventional Cardiology

Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System for Severe Tricuspid Regurgitation: A Multicenter, First-in-Human 1-Year Observation

First Commercial Multicenter Experience With the PASCAL Transcatheter Valve Repair System for Tricuspid Regurgitation

First Report of 2-Year Outcomes With a Next-Generation Left Atrial Appendage Closure Device: Final Results From the PINNACLE FLX IDE Trial

Predictors of Device-Related Thrombus Following LAA Occlusion

Low 1-Year Stroke Risk After Commercial Watchman Use

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

LAA Occlusion With Amplatzer Amulet May Have Edge Over DOACs

AMULET IDE: One-Year Device Closure and Device-Related Thrombus Outcomes From a Randomized Trial of Amulet versus Watchman for Left Atrial Appendage Occlusion

SWISS-APERO: A Randomized Trial of the Amulet Versus Watchman FLX Devices for Left Atrial Appendage Closure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content